Journal Watch · Frontiers in Immunology · 2026
Natural polysaccharides as immune adjuvants to overcome immune checkpoint inhibitor resistance: mechanistic insights, clinical evidence, and translational challenges.
Rather than presenting rigid standardized treatment schemes, this review constructs a realistic, mechanism-guided roadmap to accelerate the clinical translation of natural polysaccharide ICI adjuvants.
TL;DR
Rather than presenting rigid standardized treatment schemes, this review constructs a realistic, mechanism-guided roadmap to accelerate the clinical translation of natural polysaccharide ICI adjuvants.
Key findings
- Advanced technical tools including AI-assisted glycomics and graph neural networks, alongside synthetic biology platforms, provide new solutions to resolve structural identification and mass-production limitations.
- Integrating polysaccharide production with Industry 6.0 intelligent manufacturing and circular bioeconomy models can balance therapeutic development and global sustainable development targets.
- Finally, we propose a precision medicine workflow incorporating multi-layer biomarkers (gut microbial profiles, intratumoral immune signatures, glycomic fingerprints) to optimize patient stratification and individualized dosing.
- Rather than presenting rigid standardized treatment schemes, this review constructs a realistic, mechanism-guided roadmap to accelerate the clinical translation of natural polysaccharide ICI adjuvants.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Cumulative preclinical findings and early-phase clinical observations suggest synergistic therapeutic benefits for polysaccharide plus ICI combinations. Still, robust evidence from large-scale randomized Phase III trials remains absent, and polysaccharides cannot yet be validated as standard adjuvants to resolve ICI resistance. In this review, we systematically dissect the structural basis governing polysaccharide immunomodulation and elaborate four core mechanisms for overcoming immunotherapy resistance: repolarizing tumor-associated macrophages toward anti-tumor phenotypes, alleviating CD8<sup>+</sup> T cell exhaustion, regulating bidirectional gut microbiota-immune crosstalk, and inhibiting tumor-intrinsic immune escape cascades. We further summarize persistent translational bottlenecks: structural heterogeneity, nonstandard quality control, low oral bioavailability, and inconsistent clinical trial protocols, and conduct a head-to-head comparison between polysaccharides and mainstream immunostimulants (CpG oligodeoxynucleotides, STING agonists, fecal microbiota transplantation).
Full abstract (original)
Background: Immune checkpoint inhibitors (ICIs) have redefined the treatment landscape of advanced malignancies, yet primary and acquired resistance severely limits their therapeutic efficacy across most solid tumors. Even in biomarker-stratified patient cohorts, objective response rates frequently fall below 25%. Natural polysaccharides have emerged as a unique category of immune adjuvants. Beyond activating innate immune receptors including Toll-like receptor 4 and downstream MyD88 signaling, such macromolecules remodel the gut microbiota-metabolite axis and partially reverse immunosuppressive tumor microenvironments.
What they did: Cumulative preclinical findings and early-phase clinical observations suggest synergistic therapeutic benefits for polysaccharide plus ICI combinations. Still, robust evidence from large-scale randomized Phase III trials remains absent, and polysaccharides cannot yet be validated as standard adjuvants to resolve ICI resistance. In this review, we systematically dissect the structural basis governing polysaccharide immunomodulation and elaborate four core mechanisms for overcoming immunotherapy resistance: repolarizing tumor-associated macrophages toward anti-tumor phenotypes, alleviating CD8<sup>+</sup> T cell exhaustion, regulating bidirectional gut microbiota-immune crosstalk, and inhibiting tumor-intrinsic immune escape cascades. We further summarize persistent translational bottlenecks: structural heterogeneity, nonstandard quality control, low oral bioavailability, and inconsistent clinical trial protocols, and conduct a head-to-head comparison between polysaccharides and mainstream immunostimulants (CpG oligodeoxynucleotides, STING agonists, fecal microbiota transplantation).
Results & conclusions: Advanced technical tools including AI-assisted glycomics and graph neural networks, alongside synthetic biology platforms, provide new solutions to resolve structural identification and mass-production limitations. Integrating polysaccharide production with Industry 6.0 intelligent manufacturing and circular bioeconomy models can balance therapeutic development and global sustainable development targets. Finally, we propose a precision medicine workflow incorporating multi-layer biomarkers (gut microbial profiles, intratumoral immune signatures, glycomic fingerprints) to optimize patient stratification and individualized dosing. Rather than presenting rigid standardized treatment schemes, this review constructs a realistic, mechanism-guided roadmap to accelerate the clinical translation of natural polysaccharide ICI adjuvants.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1914914 · PubMed 42626083.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
Rather than presenting rigid standardized treatment schemes, this review constructs a realistic, mechanism-guided roadmap to accelerate the clinical translation of natural polysaccharide ICI adjuvants.
What type of study is this?
It is a randomised / controlled clinical trial, published in Frontiers in Immunology in 2026. Cumulative preclinical findings and early-phase clinical observations suggest synergistic therapeutic benefits for polysaccharide plus ICI combinations.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1914914. PubMed ID: 42626083. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/natural-polysaccharides-as-immune-adjuvants-to-overcome-immune-checkpoin-914914/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides